Vascular endothelial growth factor-A and changes in a tumor-bearing mouse model with Lewis lung cancer

Tsai,Meng-shu; Chang,Cheng-chi; Kuo,Min-liang; Wu,Ying-tai

doi:10.3892/ol.2011.380

Vascular endothelial growth factor-A and changes in a tumor-bearing mouse model with Lewis lung cancer

Authors:
- Meng-shu Tsai
- Cheng-chi Chang
- Min-liang Kuo
- Ying-tai Wu
View Affiliations

Affiliations: School and Graduate Institute of Physical Therapy, College of Medicine, National Taiwan University, Zhongzheng District, Taipei 100, Taiwan, R.O.C., Graduate Institute of Oral Biology, School of Dentistry, National Taiwan University, Taipei 100, Taiwan, R.O.C., Graduate Institute of Toxicology, College of Medicine, National Taiwan University, Zhongzheng District, Taipei 100, Taiwan, R.O.C.
Published online on: August 9, 2011 https://doi.org/10.3892/ol.2011.380
Pages: 1143-1147

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Vascular endothelial growth factor-A (VEGF-A) affects tumor growth and metastasis through stimulation of angiogenesis. The purpose of this study was to describe features of Lewis lung cancer (LLC) in mice and compare the serum VEGF-A levels with those of normal control mice. Two groups of mice were compared: one was subcutaneously injected with LLC cells (n=16) and the other served as the normal control (n=6). The serum VEGF-A levels were measured by ELISA prior to inoculation, and at 7, 21 and 35 days post-inoculation. The tumor weight and the metastatic condition were evaluated on day 35. Changes in body weight and serum VEGF-A concentration over a period of time were compared between the groups using generalized estimating equations. The relationship between the primary tumor and the metastatic condition was analyzed using the Spearman's rank correlation test. The survival rate was 56.3% on day 35 post-tumor inoculation. No difference was found between the groups with regard to gastrocnemius muscle weight on day 35 post-inoculation [0.1315±0.0066 g vs. 0.1308±0.0069 g (normal control)]. In tumor-bearing mice, the weight gain at sacrifice was less (0.24±0.45 vs. 1.93±0.47 g, P=0.01), the final mean tumor volume and weight were 4264.69±1038.32 mm3 and 3.70±0.83 g, the number of nodules in the lungs and livers was 6.33 (range 0-20) and 2.22 (range 0-11), respectively, and the serum VEGF-A levels were significantly higher than those of control mice. In conclusion, lower body weight gain, metastasis in the liver and lungs, and elevated VEGF-A levels are features of LLC in mice.

View Figures

View References

1	Parkin M, Bray F, Ferlay J and Pisani P: Global Cancer Statistics, 2002. CA Cancer J Clin. 55:74–108. 2005. View Article : Google Scholar
2	Department of Health EY R.O.C. (Taiwan). Statistics of causes of death. Department of Health, Executive Yuan, R.O.C. (Taiwan); 2008
3	Tisdale MJ: Mechanisms of cancer cachexia. Physiol Rev. 89:381–410. 2009. View Article : Google Scholar : PubMed/NCBI
4	O’Reilly MS, Holmgren L, Shing Y, et al: Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell. 79:315–328. 1994.PubMed/NCBI
5	Maniwa Y, Okada M, Ishii N and Kiyooka K: Vascular endothelial growth factor increased by pulmonary surgery accelerates the growth of micrometastases in metastatic lung cancer. Chest. 114:1668–1675. 1998. View Article : Google Scholar : PubMed/NCBI
6	Savai R, Wolf JC, Greschus S, et al: Analysis of tumor vessel supply in Lewis lung carcinoma in mice by fluorescent microsphere distribution and imaging with micro-and flat-panel computed tomography. Am J Pathol. 167:937–946. 2005. View Article : Google Scholar
7	Chen HC: Studies on the inhibitory mechanism of angiogenesis inhibitor, endostatin. Department of Biological Sciences, National Sun Yat-Sen University; pp. 1082000
8	Rashidi B, Yang M, Jiang P, et al: A highly metastatic Lewis lung carcinoma orthotopic green fluorescent protein model. Clin Exp Metastasis. 18:57–60. 2000. View Article : Google Scholar : PubMed/NCBI
9	Liu X, Wu Z, Zuo S, Zhou Y, Chen Y and Wang X: Establishment of orthotopic Lewis lung cancer model in mouse. Chin J Lung Cancer. 13:42–47. 2010.PubMed/NCBI
10	Argilés JM, Figueras M, Ametller E, et al: Effects of CRF2R agonist on tumor growth and cachexia in mice implanted with Lewis lung carcinoma cells. Muscle Nerve. 37:190–195. 2008.PubMed/NCBI
11	Lippman MM, Laster WR, Abbott BJ, Venditti J and Baratta M: Antitumor activity of macromomycin B (NSC 170105) against murine leukemias, melanoma, and lung carcinoma. Cancer Res. 35:939–945. 1975.PubMed/NCBI
12	Li LM, Shin DM and Fidler IJ: Intrabronchial implantation of the Lewis lung tumor cell does not favor tumorigenicity and metastasis. Invasion Metastasis. 10:129–141. 1990.PubMed/NCBI
13	Savai R, Langheinrich AC, Schermuly RT, et al: Evaluation of angiogenesis using micro-computed tomography in a xenograft mouse model of lung cancer. Neoplasia. 11:48–56. 2009.PubMed/NCBI
14	Zhang Z, Hatori T and Nonaka H: An experimental model of brain metastasis of lung carcinoma. Neuropathology. 28:24–28. 2008. View Article : Google Scholar : PubMed/NCBI
15	Argiles JM, Figueras M, Ametller E, et al: Effects of CRF2R agonist on tumor growth and cachexia in mice implanted with Lewis lung carcinoma cells. Muscle Nerve. 37:190–195. 2008. View Article : Google Scholar : PubMed/NCBI
16	Harlos JP and Weiss L: Differences in the peripheries of Lewis lung tumor cells growing in different sites in the mouse. Int J Cancer. 32:745–750. 1983. View Article : Google Scholar : PubMed/NCBI
17	Papetti M and Herman IM: Mechanisms of normal and tumor-derived angiogenesis. Am J Physiol Cell Physiol. 282:C947–970. 2002. View Article : Google Scholar : PubMed/NCBI
18	Zhan P, Wang J, Lv XL, et al: Prognostic value of vascular endothelial growth factor expression in patients with lung cancer: A systematic review with meta-analysis. J Thorac Oncol. 4:1094–1103. 2009. View Article : Google Scholar : PubMed/NCBI
19	Shimanuki Y, Takahashi K, Cui R, et al: Role of serum vascular endothelial growth factor in the prediction of angiogenesis and prognosis for non-small cell lung cancer. Lung. 183:29–42. 2005. View Article : Google Scholar : PubMed/NCBI
20	Li J, Dong X, Xu Z, et al: Endostatin gene therapy enhances the efficacy of paclitaxel to suppress breast cancers and metastases in mice. J Biomed Sci. 15:99–109. 2008. View Article : Google Scholar : PubMed/NCBI
21	Maillard CM, Bouquet C, Petitjean MM, et al: Reduction of brain metastases in plasminogen activator inhibitor-1-deficient mice with transgenic ocular tumors. Carcinogenesis. 29:2236–2242. 2008. View Article : Google Scholar : PubMed/NCBI
22	Hotz HG, Hines OJ, Masood R, et al: VEGF antisense therapy inhibits tumor growth and improves survival in experimental pancreatic cancer. Surgery. 137:192–199. 2005. View Article : Google Scholar : PubMed/NCBI
23	Langley RR and Fidler IJ: The seed and soil hypothesis revisited–the role of tumor-stroma interactions in metastasis to different organs. Int J Cancer. 128:2527–2535. 2011.
24	Chung DC, Zetter BR and Brodt P: Lewis lung carcinoma variants with differing metastatic specificities adhere preferentially to different defined extracellular matrix molecules. Invasion Metastasis. 8:103–117. 1988.
25	Llovera M, Garcia-Martinez C, Lopez-Soriano J, et al: Protein turnover in skeletal muscle of tumour-bearing transgenic mice overexpressing the soluble TNF receptor-1. Cancer Lett. 130:19–27. 1998. View Article : Google Scholar : PubMed/NCBI
26	Van Royen M, Carbo N, Busquets S, et al: DNA fragmentation occurs in skeletal muscle during tumor growth: A link with cancer cachexia? Biochem Biophys Res Commun. 270:533–537. 2000.PubMed/NCBI
27	Al-Majid S and McCarthy DO: Resistance exercise training attenuates wasting of the extensor digitorum longus muscle in mice bearing the colon-26 adenocarcinoma. Biol Res Nurs. 2:155–166. 2001. View Article : Google Scholar : PubMed/NCBI
28	Gupta MK and Qin RY: Mechanism and its regulation of tumor-induced angiogenesis. World J Gastroenterol. 9:1144–1155. 2003.PubMed/NCBI
29	Wicki A and Christofori G: The angiogenic switch in tumorigenesis. Tumor angiogenesis. Marme D and Fusenig N: Springer Berlin; Heidelberg, New York: pp. 67–88. 2008, View Article : Google Scholar
30	Austin K, Sookhai S, Wang J, Pedmond K, Kirwan W and Pedmond H: Anti-angiogenic therapy attenuates micrometastatic tumour growth in a Lewis lung carcinoma model. Ir J Med Sci. 170:112001. View Article : Google Scholar
31	Erdem F, Gündogdu M and Kiziltunç A: Serum vascular endothelial growth factor level in Patients with hematological malignancies. Eur J Gen Med. 3:116–120. 2006.
32	Vicioso L, Gonzalez FJ, Alvarez M, et al: Elevated serum levels of vascular endothelial growth factor are associated with tumor-associated macrophages in primary breast cancer. Am J Clin Pathol. 125:111–118. 2006. View Article : Google Scholar : PubMed/NCBI
33	Poon RT, Lau CP, Cheung ST and Yu WC: Quantitative correlation of serum levels and tumor expression of vascular endothelial growth factor in patients with hepatocellular carcinoma. Cancer Res. 63:6121–6126. 2003.PubMed/NCBI
34	Kivela R, Silvennoinen M, Lehti M, Jalava S, Vihko V and Kainulainen H: Exercise-induced expression of angiogenic growth factors in skeletal muscle and in capillaries of healthy and diabetic mice. Cardiovasc Diabetol. 7:132008. View Article : Google Scholar : PubMed/NCBI